Nombre del producto:2-Methylpiperazine

IUPAC Name:2-methylpiperazine

CAS:109-07-9
Fórmula molecular:C5H12N2
Pureza:98%
Número de catálogo:CM120079
Peso molecular:100.17

Unidad de embalaje Stock disponible Precio($) Cantidad
CM120079-100g in stock ľŤ

Sólo para uso en I+D..

Formulario de consulta

   refresh    

Detalles del producto

Núm. De CAS :109-07-9
Fórmula molecular:C5H12N2
Punto de fusión:-
Código de sonrisas:CC1NCCNC1
Densidad:
Número de catálogo:CM120079
Peso molecular:100.17
Punto de ebullición:
Nº Mdl:MFCD00005954
Almacenamiento:

Category Infos

Piperazines
Piperazine is an organic compound consisting of a six-membered ring containing two nitrogen atoms in opposite positions in the ring. The chemical formula of piperazine is C4H10N2, and it is an important pharmaceutical intermediate. Pyrimidines and piperazines are known to be the backbone of many bulk compounds and important core structures for approved drugs; studies have shown that combining a pyridine ring with a piperazine moiety within a single structural framework enhances biological activity.
Fuel Cell Materials
Fuel Cells is a highly efficient, clean and renewable energy technology with many advantages such as low emissions, high efficiency, quiet operation and flexibility. They can use many different fuels, such as hydrogen, methanol, natural gas and biomass, making them highly adaptable and flexible. Fuel cell materials are essential components in the construction and operation of fuel cells, which are devices that convert chemical energy from fuels into electrical energy through an electrochemical process. There are several types of fuel cells, such as proton exchange membrane fuel cells (PEMFCs), solid oxide fuel cells (SOFCs), and molten carbonate fuel cells (MCFCs), each requiring different materials for their functioning.

Column Infos

Fenebrutinib
Roche’s investigational drug, Fenebrutinib has shown brain penetration and significant reduction in lesions in patients with relapsing multiple sclerosis (MS) from the recent release of new data from Phase II FENopta study. Fenebrutinib is a potent and highly selective Bruton’s tyrosine kinase (BTK) inhibitor, and currently the only reversible inhibitor being tested in Phase III MS trials. BTK inhibitor is involved in key pathological features of MS, including B-cell development and activation.